Aiming to destroy ‘untreatable cancer’… Diagnostics industry boosts colon and pancreatic cancer diagnostic technology

Biodiversity companies are expanding investment in diagnostic technology research that focuses on types of cancer that are difficult to detect early, such as colon cancer and pancreatic cancer. Because early diagnosis is the key to cancer treatment and a positive prognosis, there is a huge unmet need in the medical community for modern diagnostic technologies. Companies are accelerating development, including the discovery of cancer diagnostic biomarkers and the introduction of artificial intelligence (AI) technology.

According to the industry on the 1st, Vertis recently developed pancreatic cancer diagnosis technology and confirmed a high accuracy of 92%. Vertis used mass spectrometry and bioinformatics technology to select 12 protein biomarkers that were differentially expressed in a control group including pancreatic adenocarcinoma patients, healthy individuals, and patients with benign pancreatic diseases. legal. Subsequently, a multi-marker panel containing 13 types of biomarkers was developed by combining the blood biomarker ‘CA19-9’, which is currently used for screening for pancreatic cancer.

Vertis developed a diagnostic test model using machine learning and evaluated its diagnostic performance for pancreatic cancer screening. The model showed an accuracy of 92% for all stages of pancreatic ductal adenocarcinoma and stages 1 and 2 pancreatic ductal adenocarcinoma, respectively. The company is pursuing the commercialization of ‘Pank Check’, a blood test for early diagnosis of pancreatic cancer To obtain approval from the Ministry of Food and Drug Safety, the company is conducting clinical trials by obtaining blood samples from 513 a person , including 220 pancreatic cancer patients.

Prestige Biopharma is developing a pancreatic cancer diagnostic kit using the pancreatic adenocarcinoma overexpression factor (PAUF) platform. PAUF is a tumor-specific biomarker overexpressed in more than 80% of pancreatic cancer cases associated with early progression and metastasis. Prestige Biopharma is developing a pancreatic cancer treatment drug, ‘PBP1510’, and based on research on this substance, it has created a pancreatic cancer diagnostic kit that detects PAUF as a biomarker. Last year, they attended the International Medical Equipment Exhibition (MEDICA) and announced that they would register and release worldwide as an in vitro diagnostic medical device. The goal is to build a system that goes from pancreatic cancer diagnosis to treatment by developing the diagnostic tool and PBP1510 at the same time.

Deepnoid is pursuing the development of diagnostic technology for various types of cancer, including colon cancer, through pathological image analysis using AI technology. In a colorectal cancer pathology image analysis study conducted with Professor Joseph Jeong from the Department of Pathology at the Catholic University of Korea, the accuracy of colorectal cancer diagnosis was improved by AI-based analysis technology that compared feature extractors to find out if there was colorectal cancer. normal and its four subtypes. In addition, Hu&Biome signed a strategic partnership with Bazyme Biotech in China on the 25th of last month to develop early diagnosis technology for colorectal cancer using the microbiome. The two companies plan to discover microbiome-based biomarkers for the early diagnosis of colon cancer and pursue a joint validation research project.

The size of the cancer diagnostics market is growing steadily. Allied Market Research, a global research company, reports that the global in vitro diagnostic market size for cancer diagnosis registered an average annual growth rate of 5.6% from approximately $9,311.59 million (KRW 12.38 trillion) in 2019, to approximately $13,371.18 million (KRW). 13.37118 trillion) in 2027. It is expected to reach 17.78 trillion won).